PMID- 21831297
OWN - NLM
STAT- MEDLINE
DCOM- 20111129
LR  - 20211020
IS  - 1471-2377 (Electronic)
IS  - 1471-2377 (Linking)
VI  - 11
DP  - 2011 Aug 10
TI  - Overnight switch from ropinirole to transdermal rotigotine patch in patients with 
      Parkinson disease.
PG  - 100
LID - 10.1186/1471-2377-11-100 [doi]
AB  - BACKGROUND: A recent trial involving predominantly Caucasian subjects with 
      Parkinson Disease (PD) showed switching overnight from an oral dopaminergic 
      agonist to the rotigotine patch was well tolerated without loss of efficacy. 
      However, no such data have been generated for Korean patients. METHODS: This 
      open-label multicenter trial investigated PD patients whose symptoms were not 
      satisfactorily controlled by ropinirole, at a total daily dose of 3 mg to 12 mg, 
      taken as monotherapy or as an adjunct to levodopa. Switching treatment from oral 
      ropinirole to transdermal rotigotine was carried out overnight, with a dosage 
      ratio of 1.5:1. After a 28-day treatment period, the safety and tolerability of 
      switching was evaluated. Due to the exploratory nature of this trial, the effects 
      of rotigotine on motor and nonmotor symptoms of PD were analyzed in a descriptive 
      manner. RESULTS: Of the 116 subjects who received at least one treatment, 99 
      (85%) completed the 28-day trial period. Dose adjustments were required for 11 
      subjects who completed the treatment period. A total of 76 treatment-emergent 
      adverse events (AEs) occurred in 45 subjects. No subject experienced a serious 
      AE. Thirteen subjects discontinued rotigotine prematurely due to AEs. Efficacy 
      results suggested improvements in both motor and nonmotor symptoms and quality of 
      life after switching. Fifty-two subjects (46%) agreed that they preferred using 
      the patch over oral medications, while 31 (28%) disagreed. CONCLUSIONS: Switching 
      treatment overnight from oral ropinirole to transdermal rotigotine patch, using a 
      dosage ratio of 1.5:1, was well tolerated in Korean patients with no loss of 
      efficacy. TRIAL REGISTRATION: This trial is registered with the ClincalTrails.gov 
      Registry (NCT00593606).
FAU - Kim, Han-Joon
AU  - Kim HJ
AD  - Department of Neurology and Movement Disorder Center, Parkinson Disease Study 
      Group, and Neuroscience Research Institute, BK21, College of Medicine, Seoul 
      National University Hospital, Seoul, Korea. brain@snu.ac.kr
FAU - Jeon, Beom S
AU  - Jeon BS
FAU - Lee, Won Yong
AU  - Lee WY
FAU - Lee, Myoung Chong
AU  - Lee MC
FAU - Kim, Jae Woo
AU  - Kim JW
FAU - Kim, Jong-Min
AU  - Kim JM
FAU - Ahn, Tae-Beom
AU  - Ahn TB
FAU - Cho, Jinwhan
AU  - Cho J
FAU - Chung, Sun Ju
AU  - Chung SJ
FAU - Grieger, Frank
AU  - Grieger F
FAU - Whitesides, John
AU  - Whitesides J
FAU - Boroojerdi, Babak
AU  - Boroojerdi B
LA  - eng
SI  - ClinicalTrials.gov/NCT00593606
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20110810
PL  - England
TA  - BMC Neurol
JT  - BMC neurology
JID - 100968555
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Indoles)
RN  - 030PYR8953 (ropinirole)
SB  - IM
MH  - Administration, Cutaneous
MH  - Administration, Oral
MH  - Antiparkinson Agents/*administration & dosage/adverse effects/pharmacokinetics
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Indoles/*administration & dosage/adverse effects/pharmacokinetics
MH  - Male
MH  - Middle Aged
MH  - Parkinson Disease/*drug therapy
PMC - PMC3166898
EDAT- 2011/08/13 06:00
MHDA- 2011/12/13 00:00
PMCR- 2011/08/10
CRDT- 2011/08/12 06:00
PHST- 2011/02/22 00:00 [received]
PHST- 2011/08/10 00:00 [accepted]
PHST- 2011/08/12 06:00 [entrez]
PHST- 2011/08/13 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
PHST- 2011/08/10 00:00 [pmc-release]
AID - 1471-2377-11-100 [pii]
AID - 10.1186/1471-2377-11-100 [doi]
PST - epublish
SO  - BMC Neurol. 2011 Aug 10;11:100. doi: 10.1186/1471-2377-11-100.